Michigan Medicine, MedImmune to collaborate on diabetes, metabolic disease research

Ann Arbor-based Michigan Medicine is partnering with MedImmune, the global biologics research and development subsidiary of AstraZeneca, on a three-year research alliance to develop innovative therapies to prevent and treat diabetes, obesity and other metabolic disorders.

Researchers will explore how the central nervous system and peripheral tissues rely on and affect one another in these types of diseases. Researchers will also study genetic models to identify targets to treat related diseases.

"Every day, we're making new connections between University of Michigan researchers and potential industry partners, facilitated by our Fast Forward Medical Innovation team," said Stephen Kunkel, PhD, senior associate dean for research at the University of Michigan Medical School. "With the ultimate goal of having a positive impact on patients, this collaboration with MedImmune is an opportunity for our researchers from multiple disciplines to work with a company whose strategies align with our deep strengths in diabetes and metabolic diseases."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars